The White House withdrew Heidi Overton’s nomination to lead the Food and Drug Administration, ending her bid for the agency’s top post. According to US News, the withdrawal came amid growing indications Overton lacked the votes needed to win Senate confirmation.

According to NBC News, Before Overton’s September hearing, Sen. Bill Cassidy questioned her managerial experience and said it left her poorly prepared to lead the FDA. According to US News, Cassidy also called Overton’s support for Trump’s proposal to split combination vaccines, including the measles, mumps and rubella shot, “almost disqualifying.”

According to NBC News, Sen. Susan Collins of Maine told NBC the previous week that she remained undecided and needed answers, while Sen. Lisa Murkowski declined to reveal her intended vote. At the confirmation hearing, Murkowski questioned Overton about political pressure involving access to mifepristone and criticized her for not taking a clear position.

According to NBC News, the FDA was scheduled to complete its safety review of mifepristone in March, a pending decision described as among the agency’s most consequential. Before joining the White House, Overton served as chief policy officer at the conservative America First Policy Institute.

According to US News, the Associated Press reported that senators from both parties questioned whether Overton would break with Trump, particularly over his unsupported claims about childhood-vaccine dangers. According to NBC News, Trump’s first nominee to lead the CDC, former congressman Dave Weldon, lacked sufficient Republican support; the Senate later confirmed Erica Schwartz in August.